Iimura Y, Kurokawa T, Andoh S, Kanemoto Y, Kawamata T, Yazawa K, Sato A, Yokoyama K, Imai Y, Tsurita G, et al. Association between thiamine decrease and neuropsychiatric symptoms in gastrointestinal and hematological cancer patients receiving chemotherapy. Biomedicine & Pharmacotherapy. 2021
Kaito Y, Hirano M, Futami M, Nojima M, Tamura H, Tojo A, Imai Y. CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. Oncology Letters. 2021
Shohei Andoh, Kazuaki Yokoyama, Sanshiro Uchida, Junya Makiyama, Toyotaka Kawamata, Hiroshi Yasui, Yasunori Ota, Yoichi Imai, Arinobu Tojo. [Cooccurrence of classic Hodgkin lymphoma and multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2021. 62. 1. 14-19
Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, Tamura H, Handa H, Tsukune Y, Sasaki M, et al. Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. International Journal of Clinical Oncology. 2021
Kaito Y, Konuma T, Monna-Oiwa M, Kato S, Isobe M, Okabe M, Imai Y, Takahashi S, Tojo A. Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation. International Journal of Laboratory Hematology. 2021
今井陽一. 骨髄腫におけるliquid biopsy. Current Therapy. 2020. 38. 6. 119-119
Mariko Ishibashi, Ryosuke Kinoshita, Koiti Inokuchi, Hiroshi Handa, Makoto Sasaki, Norio Komatsu, Yoichi Imai, Norina Hiroike, Junji Tanaka, Sakae Tanosaki, et al. Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. BLOOD. 2019. 134
1988 - 1992 The University of Tokyo School of Medicine
Work history (7)：
2016/07 - 現在 The University of Tokyo Hospital The Institute of Medical Science Research Hospital, Department of Hematology/Oncology
2010/10 - 2016/06 Tokyo Women's Medical University Faculty of Medicine, Faculty of Medicine
2008/01 - 2010/09 The University of Tokyo Graduate School of Medicine
2004/03 - 2007/12 Harvard University
2002/09 - 2004/02 The University of Tokyo Heamatology and Oncology, Faculty of Medicine University Hospital
2001/04 - 2002/08 日本学術振興会 特別研究員
1999/04 - 2001/03 The University of Tokyo Heamatology and Oncology, Faculty of Medicine University Hospital
Show all
Committee career (7)：
2020/01 - 現在 日本癌学会 評議員
- 現在 日本骨髄腫学会 代議員
- 現在 日本血液学会 評議員
2020/09 - 2022/05 日本骨髄腫学会 学会誌編集委員会 委員
2015 - 2020 日本血液学会 プログラム企画委員
2018 - 2019 日本骨髄腫学会 第43, 44回学術集会プログラム委員
日本血液学会 問題作成委員
Show all
Awards (4)：
2014/01 - IMF (International Myeloma Foundation) IMF-JAPAN Special Research Grant Development of novel targeted therapies in the treatment of multiple myeloma through elucidation of molecular mechanism of oncogenesis mediated by calcineurin
2001/11 - 日本臨床血液学会 奨励賞 骨髄異形成症候群におけるAML1遺伝子異常の解析
2001/04 - 日本血液学会 奨励賞 Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis
2001/04 - 日本内科学会 奨励賞 ヒト造血器腫瘍におけるSmad遺伝子の変異解析
Association Membership(s) (8)：
米国血液学会
, THE MOLECULAR BIOLOGY SOCIETY OF JAPAN
, THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER
, THE JAPANESE CANCER ASSOCIATION
, 日本造血細胞移植学会
, 日本骨髄腫学会
, THE JAPANESE SOCIETY OF HEMATOLOGY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
